Mucosal Interleukin‐10 depletion in steroid‐refractory Crohn's disease patients. Issue 10 (27th September 2022)

• Record Type: Journal Article
• Authors: Carrasco, Anna; Tristán, Eva; Fernández‐Bañares, Fernando; Martín‐Cardona, Albert; Aceituno, Montserrat; Zabana, Yamile; Fluvià, Lourdes; Hernández, José María; Lorén, Violeta; Manyé, Josep; Salas, Antonio; Andújar, Xavier; Loras, Carme; Esteve, Maria
• Is Part Of: Immunity, inflammation and disease. Volume 10:Issue 10(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-09-27
• Subjects: Crohn's disease -- inflammatory bowel disease -- Interleukin‐10 -- intestinal compartmentalization -- steroid resistance; Immunology -- Periodicals; Immunity -- Periodicals; Inflammation -- Periodicals; 616.079
• DOI: 10.1002/iid3.710
• Languages: English
• ISSNs: 2050-4527

Abstract

Abstract: Background: Previous studies suggested that Interleukin‐10 (IL‐10) depletion in Crohn's disease (CD) could predict outcome. Aim: To determine IL‐10 in blood and at different intestinal locations in patients with active CD and to assess its potential prognostic capacity to identify aggressive CD. Methods: Twenty‐three patients with CD were included. Ulcerative colitis (UC), infectious colitis and healthy individuals acted as controls. Serum and mucosal samples were taken at baseline and 1 month after steroid initiation in CD patients. Patients were classified according to steroid response. Control samples were obtained from different intestinal locations. IL‐10 expression was measured with real‐time polymerase chain reaction, immunofluorescence (intestine) and ELISA (serum, biopsy cultures' supernatants and tissue homogenates). Results: CD and UC showed an increase in IL‐10 messenger RNA (mRNA) versus controls ( p < .0001) in mucosa, whereas IL‐10 protein secretion was increased in all types of intestinal inflammation ( p < .001). No differences in IL‐10 mRNA were found in CD at baseline regarding steroid response, but levels decreased in non‐responders versus responders ( p = .027) and were restored with rescue therapy. Serum IL‐10 was increased in steroid‐refractory CD at baseline and after treatment. Conclusions: Abnormal IL‐10 levels in refractory patients in both mucosa and blood have physiopathological relevance and may have potential clinical applications. Abstract : (1) Increased messenger RNA and protein lL‐10 levels in intestinal mucosa is a shared immunological response of both active Crohn's disease (CD) and ulcerative colitis. (2) CD patients showed a particular Interleukin‐10 (IL‐10) pattern related to steroid response, with depletion of IL‐10 at mucosal compartment in steroid resistant patients and restoration after successful rescue therapy. (3) At peripheral blood, high levels of circulating IL‐10 were found in steroid‐resistant CD patients before and after treatment initiation, suggesting potential clinical applications of IL‐10 as predictor of treatment response.